Research.Patient.info
High Risk Smoldering Multiple Myeloma (HR-SMM) research hub
2 indexed studies · 1 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
This study looks at adults with high-risk smoldering multiple myeloma, an early form of blood cancer. Researchers are comparing a newer medicine called linvoseltamab against an established treatment called daratumumab. The goal is to see which medicine is better at delaying or stopping the condition from turning into active cancer.
Italy · Spain · Poland - recruitingPHASE3
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study looks at two different drugs, linvoseltamab and daratumumab, for people with a condition called High-Risk Smoldering Multiple Myeloma (HR-SMM). Doctors want to find out if linvoseltamab is better at stopping this condition from turning into active Multiple Myeloma, a type of blood cancer.
United States · Japan · South Korea